Skip to main content
Back
Watch Compare

Biofrontera Inc.

Data quality: 100%
Also listed as BFRIW NASDAQ
BFRI
NASDAQ Manufacturing Chemicals
$1.06
▼ $0.03 (-2.75%)
6 months return
—
Momentum
Neutral
5Y revenue growth
14.69%

Growth

Revenue Growth (5Y)
14.69%
Above sector avg (1.82%)
Revenue (1Y)11.75%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
N/A
ROIC-540.54%
Net Margin-25.26%
Op. Margin-27.21%

Safety

Debt / Equity
N/A
Current Ratio1.15
Interest CoverageN/A

Valuation

PE (TTM|NTM|2027)
-1.16 | 7.36 | 7.50
Above sector avg (-1.49)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Revenue grew 14.69% annually over 5 years — strong growth
Negative free cash flow of -13.36 M
Capital efficient — spends only 0.00% of revenue on capex

Price History

Financial Trends

Analyst Price Target

2 analysts
Buy
+466.0%
upside to target
Current
$1.06
Consensus Target
$6.00
$3.00
Low
$9.00
High
Forecast
Forward P/E
7.36
Forward EPS
$0.14
Est. Revenue
54.70 M

Earnings Surprises

EPS
Reported Estimate Forecast
Next: Q1 2026 · EPS Est: -$0.05 · Rev Est: 10.25 M
Q12025 Q22025 Q32025 Q42025 Q1 '26 Q2 '26
Reported -$0.51 -$0.57 -$0.57 $0.50 — —
Estimate -$0.29 -$0.39 -$0.56 $0.10 -$0.05 -$0.11
Surprise -75.31% -45.10% -1.55% +398.10% — —

Growth

Rev 5Y: 14.69% · Earnings 1Y: N/A
Revenue Growth (1Y) 11.75% Revenue Growth (3Y) 10.64%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 14.69% Earnings Growth (5Y) N/A

Profitability

ROE: N/A · Net Margin: -25.26%
Revenue (TTM) 41.71 M Net Income (TTM) -10.54 M
ROE N/A ROA -59.26%
Gross Margin N/A Operating Margin -27.21%
Net Margin -25.26% Free Cash Flow (TTM) -13.36 M
ROIC -540.54% FCF Growth (3Y) N/A

Safety

D/E: N/A · Current: 1.15
Debt / Equity N/A Current Ratio 1.15
Interest Coverage N/A Asset Turnover 2.35
Working Capital 1.86 M Tangible Book Value -2.60 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: -1.16 · EV/EBITDA: N/A
P/E Ratio -1.16 Forward P/E 7.36
P/B Ratio N/A P/S Ratio 0.29
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 0.22 Fwd Earnings Yield 13.59%
FCF Yield -109.78%
Market Cap 12.17 M Enterprise Value 8.76 M

Per Share

EPS: -1.04 · FCF/Share: -1.15
EPS (Diluted TTM) -1.04 Revenue / Share 3.58
FCF / Share -1.15 OCF / Share -1.15
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: 126.83% · CapEx/Rev: 0.00%
CapEx / Revenue 0.00% FCF Conversion 126.83%
SBC-Adj. FCF -14.31 M Growth Momentum -2.94

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 41.71 M 37.32 M 34.07 M 28.67 M 24.10 M
Net Income -10.54 M -17.76 M -20.13 M -640,000.0 -37.71 M
EPS (Diluted) -1.04 -3.22 -13.02 — —
Gross Profit — — — — —
Operating Income -11.35 M -17.21 M -22.68 M -18.58 M -25.20 M
EBITDA — — — — —
R&D Expenses 3.72 M 2.09 M 77,000.0 — —
SG&A Expenses 37.75 M — 38.98 M 35.14 M 36.51 M
D&A 138,000.0 600,000.0 — — —
Interest Expense — — 220,000.0 195,000.0 344,000.0
Income Tax 25,000.0 22,000.0 14,000.0 32,000.0 56,000.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 28.56 M 22.10 M 27.93 M 50.88 M 53.22 M
Total Liabilities 18.08 M 17.67 M 23.14 M 27.01 M 41.88 M
Shareholders' Equity 10.48 M 4.43 M 4.79 M 23.88 M 11.34 M
Total Debt — 3.90 M 3.90 M — —
Cash & Equivalents 6.39 M 5.91 M 1.34 M 17.21 M 24.55 M
Current Assets 18.08 M 20.70 M 23.08 M 43.14 M 46.42 M
Current Liabilities 11.90 M 12.02 M 18.09 M 20.89 M 13.84 M

Peer Comparison

vs Manufacturing sector median (1605 peers)
Metric Stock Sector Median
P/E -1.2 -1.5
P/B — 1.6
ROE % — -54.7
Net Margin % -25.3 -41.5
Rev Growth 5Y % 14.7 1.8
D/E — 0.3

Strategy Scores

1 strategy matched
Value Price/Sales Ratio Focus (Ken Fisher)
#198 of 245
28

Recent Activity

Entered Price/Sales Ratio Focus (Ken Fisher)
Apr 12, 2026